Objective:To investigate the value of mpMRI-based ultrasound-cognitive fusion guided transperineal prostate puncture biopsy in the diagnosis of patients with prostate tumors.Methods:The data of 103 patients with prostate cancer diagnosed and treated in the First People's Hospital of Nankang District from March 2022 to January 2024 were retrospectively analyzed.They were divided into a malignant group(n=46)and a benign group(n=57)according to the results of tumor malignancy in surgical and pathological examination.Both groups received mpMRI-based ultrasound-cognitive fusion guided transperineal prostate puncture biopsy and systematic puncture biopsy.The detection of benign and malignant prostate tumors by the two examination methods was statistically analyzed,the diagnosis of benign and malignant prostate tumors was compared.Results:A total of 44 cases of malignant prostate tumor and 54 cases of benign prostate tumor were detected by mpMRI-based ultrasound-cognitive fusion guided transperineal prostate puncture biopsy.Systematic puncture biopsy detected 35 cases of malignant prostate tumor and 52 cases of benign prostate tumor.The sensitivity,accuracy and negative predictive value of mpMRI-based ultrasound-cognitive fusion guided transperineal prostate puncture biopsy for prostate cancer diagnosis were 95.65%,95.15%and 96.43%,respectively,which were higher than 76.09%,84.47%and 82.54%of systematic biopsy respectively,with statistical significance(P<0.05).The diagnostic specificity and positive predictive value of mpMRI-based ultrasound-cognitive fusion guided transperineal prostate puncture biopsy for prostate cancer were 94.74%and 93.62%,respectively,compared with 91.23%and 87.50%of systemic biopsy,there were no significant differences(P>0.05).Conclusion:In summary,mpMRI-based ultrasound-cognitive fusion guided transperineal prostate puncture biopsy can effectively differentiate prostate malignancy,with high sensitivity,accuracy and negative predictive value.
维普
万方数据